Impact Of PET/CT On Treatment In Patients With Head And Neck Squamous Cell Carcinoma-Reference-Cited by-同舟云学术

Impact Of PET/CT On Treatment In Patients With Head And Neck Squamous Cell Carcinoma

Published:2024-04-09 Issue:2 Volume:78 Page:29-34
ISSN:0030-6657
Container-title:Otolaryngologia Polska
language:
Short-container-title:Otolaryngol Pol

Author:

García-Curdi Fernando¹^ORCID,Lois-Ortega Yolanda¹^ORCID,Muniesa-del Campo Ana²^ORCID,Andrés-Gracia Alejandro³^ORCID,Sebastián-Cortés José Miguel⁴^ORCID,Vallés-Varela Héctor⁴^ORCID,Lambea-Sorrosal Julio José⁵^ORCID

Affiliation:

1. Department of Otorhinolaryngology, Hospital Obispo Polanco, Teruel, Spain

2. Department of Animal Pathology, Faculty of Veterinary Sciences, University of Zaragoza, Spain

3. Department of Nuclear Medicine, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain

4. Department of Otorhinolaryngology, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain

5. Department of Medical Oncology, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain

Abstract

Introduction: Although PET/CT is effective for staging HNSCC, its impact on patient management is somewhat controversial. For this reason, we considered it necessary to carry out a study in order to verify whether PET/CT helps to improve the prognosis and treatment in patients. This study was designed to address the impact of PET-FDG imaging when used alongside CT in the staging and therapeutic management of patients with HNSCC. Material and methods: Data was collected from 169 patients diagnosed with HNSCC with both CT and PET/CT (performed within a maximum of 30 days of each other). It was evaluated whether discrepancies in the diagnosis of the two imaging tests had impacted the treatment. Results: The combined use of CT and PET/CT led to a change in the treatment of 67 patients, who represented 39.7% of the sample. In 27.2% of cases, it entailed a change in the type of treatment which the patient received. In 3.0% of the cases, using both diagnostic tests led to modifications of the therapeutic intention of our patients. Conclusions: Using PET/CT in addition to the conventional imaging method in staging resulted in more successful staging and more appropriate therapeutic decision-making.

Publisher

Index Copernicus

Link

https://otolaryngologypl.com/gicid/pdf/01.3001.0054.2561

Reference20 articles.

1. Lowe V.J., Boyd J.H., Dunphy F.R. et al.: Surveillance for Recurrent Head andNeck Cancer Using Positron Emission Tomography. J. Clin. Oncol., 2000; 18(3):651–651. doi: 10.1200/JCO.2000.18.3.651.

2. Anderson C.M., Chang T., Graham M.M. et al.: Change of Maximum Standardized Uptake Value Slope in Dynamic Triphasic [18F]-FluorodeoxyglucosePositron Emission Tomography/Computed Tomography Distinguishes Malignancy From Postradiation Inflammation in Head-and-Neck Squamous CellCarcinoma: A Prospecti. Int J Radiat Oncol Biol Phys, 2015; 91(3): 472–479.doi: 10.1016/j.ijrobp.2014.11.002.

3. Rohde M., Dyrvig A.K., Johansen J. et al.: 18F-fluoro-deoxy-glucose-positronemission tomography/computed tomography in diagnosis of head and necksquamous cell carcinoma: A systematic review and meta-analysis. Eur J Cancer., 2014; 50(13): 2271–2279. doi: 10.1016/j.ejca.2014.05.015.

4. Yankevich U., Hughes M.A., Rath T.J. et al.: PET/CT for Head and Neck Squamous Cell Carcinoma: Should We Routinely Include the Head and Abdomen? Am J Roentgenol, 2017; 208(4): 844–848. doi: 10.2214/AJR.16.16320.

5. de Bree R., Senft A., Coca-Pelaz A. et al.: Detection of Distant Metastases inHead and Neck Cancer: Changing Landscape. Adv Ther., 2018; 35(2): 161–172.doi: 10.1007/s12325-018-0662-8.